Zacks Rating on Amgen (AMGN)

Amgen (AMGN) : Zacks Investment Research ranks Amgen (AMGN) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 9 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 14 research analysts is 2.32, which indicates as a Buy.

Amgen (AMGN) : Average target price received by Amgen (AMGN) is $184.91 with an expected standard deviation of $14.63. The most aggressive target on the stock is $201, whereas the most downbeat target is $157. 11 financial analysts are currently covering the stock.


Shares of Amgen Inc. rose by 1.3% in the last five trading days and 5.32% for the last 4 weeks. Amgen Inc. is up 14.86% in the last 3-month period. Year-to-Date the stock performance stands at 9.53%. Amgen (NASDAQ:AMGN): stock turned positive on Tuesday. Though the stock opened at $174.44, the bulls momentum made the stock top out at $175.99 level for the day. The stock recorded a low of $173.66 and closed the trading day at $174.4, in the green by 0.03%. The total traded volume for the day was 2,376,437. The stock had closed at $174.35 in the previous days trading.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.